# US 2016/0355588 A1 · Bispecific CD3 and CD19 Antigen Binding Constructs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355588 A1
- Document ID: US20160355588A1
- Status: Published application
- Kind: A1
- Application number: 14/903,184
- Filed: 2014-07-11
- Published: 2016-12-08
- Earliest claimed: 2013-07-12
- Assignees: Zymeworks Inc.
- Applicants: Zymeworks Inc.
- Inventors: Gordon Yiu Kon Ng; Surjit Bhimarao Dixit; Thomas Spreter von Kreudenstein
- Web page: https://patentgrep.com/patent/US20160355588A1

## CPC

- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2887: {against CD20}
- C07K 16/30: from tumour cells
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/526: CH3 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/624: Disulfide-stabilized antibody (dsFv)
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N 2333/7051: T-cell receptor (TcR)-CD3 complex
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Bispecific antigen binding constructs are described that bind to CD3 and CD19 or CD20 antigens.

## Claims

### Claim 1

An isolated bispecific antigen binding construct comprising a first antigen-binding polypeptide construct which monovalently and specifically binds a CD19 antigen and is a Fab;
a second antigen-binding polypeptide construct which monovalently and specifically binds a CD3 antigen and is an scFv; and
a heterodimeric Fc comprising first and second Fc polypeptides each comprising a modified CH3 domain, wherein each modified CH3 domain comprises asymmetric amino acid modifications that promote the formation of a heterodimeric Fc and the dimerized CH3 domains having a melting temperature (Tm) of about 68° C. or higher, wherein the first Fc polypeptide is linked to the first antigen-binding polypeptide construct, with or without a first linker, and the second monomeric Fc polypeptide is linked to the second antigen-binding polypeptide construct with or without a second linker.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The isolated bispecific antigen binding construct of claim 1, comprising at least three, at least six, or at least 12 CDRs of variant 6754, 6751, 1853, 10151, 6475, 6749, 10152, 10153, 6476 5850, 5851, 5852, or 6325.

### Claim 4 (depends on 1)

The isolated bispecific antigen binding construct of claim 1, wherein at least one polypeptide comprises an amino acid sequence at least 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to at least one polypeptide of Variant 6754, 6751, 1853, 10151, 6475, 6749, 10152, 10153, 6476, 5850, 5851, 5852, or 6325.

### Claim 5 (depends on 1)

The isolated bispecific antigen binding construct of claim 1, wherein
a. the first antigen-binding polypeptide construct comprises the antigen-binding polypeptide construct specific for CD19 derived from an antibody selected from the group consisting of 4G7; B4; B43; BU12; CLB-CD19; Leu-12; SJ25-C1; J4.119, B43, SJ25C1, FMC63 (IgG2a) HD237 (IgG2b), Mor-208, MEDI-551, and MDX-1342;
b. and the second antigen-binding polypeptide construct comprises the binding polypeptide construct specific for CD3 derived from an antibody selected from OKT3; Teplizumab™ (MGA031, Eli Lilly); Micromet, Blinatumomab™; UCHT1; NI0401; visilizumab; X35-3, VIT3, BMA030 (BW264/56), CLB-T3/3, CRIS7, YTH12.5, F111-409, CLB-T3.4.2, WT31, WT32, SPv-T3b, 11D8, XIII-141, XIII-46, XIII-87, 12F6, T3/RW2-8C8, T3/RW2-4B6, OKT3D, M-T301, SMC2 and F101.01;
c. and/or the antigen binding construct competes with an antibody described in a or b
d. and/or a humanized version thereof.

### Claim at position 6

-7. (canceled)

### Claim 8 (depends on 1)

The isolated bispecific antigen binding construct of claim 1, wherein at least one Fc polypeptide comprises an amino acid sequence at least 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to at least one Fc polypeptide of a heterodimeric Fc of Table A or variant 6754, 6751, 1853, 10151, 6475, 6749, 10152, 10153, 6476, 5850, 5851, 5852, or 6325.

### Claim 9 (depends on 1)

The isolated bispecific antigen binding construct of claim 1, wherein the heterodimeric Fc
is a human Fc; and/or
is a human IgG1 Fc or IgG4 Fc; and/or
comprises one or more modifications in at least one of the CH3 domains; and/or
comprises one or more modifications in at least one of the CH3 domains that promote formation of a heterodimer with stability comparable to a wild-type homodimeric Fc; and/or
comprises one or more modifications in at least one of the CH3 domains as described in Table A;
further comprises at least one CH2 domain; and/or
further comprises at least one CH2 domain comprising one or more modifications; and/or
further comprises at least one CH2 domain comprising one or more modifications in at least one of the CH2 domains as described in Table B; and/or
comprises one or more modifications to promote selective binding of Fc-gamma receptors and/or complement.

### Claim 10 (depends on 1)

The isolated bispecific antigen binding construct of claim 1, wherein the dimerized CH3 domains have a melting temperature (Tm) of 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 77.5, 78, 79, 80, 81, 82, 83, 84, or 85° C. or higher.

### Claim 11 (depends on 1)

The isolated bispecific antigen binding construct of claim 1, wherein each heterodimeric Fc polypeptide is fused to each antigen-binding polypeptide construct by a linker, optionally wherein the linker is a polypeptide linker, or optionally wherein the linker comprises an IgG1 hinge region.

### Claim at position 11

-13. (canceled)

### Claim 14 (depends on 1)

The isolated bispecific antigen binding construct of claim 1, displaying reduced Fc gamma receptor binding and no associated immune-cell mediated effector activity.

### Claim 15 (depends on 1)

The isolated bispecific antigen binding construct of claim 1, wherein the bispecific antigen binding construct
is capable of synapse formation and bridging between CD19+ Raji B-cells and Jurkat T-cells as assayed by FACS and/or microscopy; and/or
mediates T-cell directed killing of CD20+ B cells in human whole blood; and/or
displays improved biophysical properties compared to v875; and/or
displays improved yield compared to v875, e.g., expressed at >10 mg/L after SEC (size exclusion chromatography); and/or
displays 10-fold better yield of the desired homogeneous species under comparable expression conditions, and/or
displays heterodimer purity, e.g., >95%.

### Claim 16 (depends on 1)

The isolated bispecific antigen binding construct of claim 1, wherein the antigen-binding construct is conjugated to a drug.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising the isolated bispecific antigen binding construct of claim 1 and a pharmaceutical carrier.

### Claim at position 16

-20. (canceled)

### Claim 21 (depends on 1)

A method of treating a cancer in a subject, the method comprising administering an effective amount of the isolated antigen-binding construct of claim 1 to the subject.

### Claim at position 18

-23. (canceled)

### Claim 24 (depends on 1)

A method of treating a condition in a subject, the method comprising administering an effective amount of the isolated antigen-binding construct of claim 1 to the subject, wherein the condition is an inflammatory condition, a proliferative disease, a minimal residual cancer, a tumorous disease, an inflammatory disease, an immunological disorder, an autoimmune disease, an infectious disease, a viral disease, an allergic reaction, parasitic reaction, a graft-versus-host disease or host-versus-graft disease or a cell malignancies, a disease associated with B cells, a disease not responsive to treatment with at least one of an anti-CD19 antibody and an anti-CD20 antibody.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

A method of producing the bispecific antigen binding construct of claim 1 comprising culturing a host cell under conditions suitable for expressing the bispecific antigen binding construct wherein the host cell comprises a polynucleotide encoding the isolated bispecific antigen binding construct of claim 1, and purifying the bispecific antigen binding construct.

### Claim 27 (depends on 1)

A method of detecting or measuring CD3 and/or CD19 in a sample comprising contacting the sample with the bispecific antigen binding construct of claim 1 and detecting or measuring the bound complex.

### Claim 28 (depends on 1)

A method of inhibiting, reducing or blocking CD3 and/or CD19 signaling in a cell comprising administering an effective amount of the bispecific antigen binding construct of claim 1 to the cell, and optional administering small molecule or a second antibody

### Claim 29 (depends on 1)

An isolated polynucleotide or set of isolated polynucleotides comprising at least one nucleic acid sequence that encodes at least one polypeptide of the isolated bispecific antigen binding construct of claim 1.

### Claim at position 25

-31. (canceled)

### Claim 32 (depends on 29)

A vector or set of vectors comprising one or more of the polynucleotides or sets of polynucleotides according to claim 29.

### Claim 33

(canceled)

### Claim 34 (depends on 29)

An isolated cell comprising a polynucleotide or set of polynucleotides according to claim 29.

### Claim at position 29

-36. (canceled)
